5-苄氧基苄基尿嘧啶 | 28495-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-苄氧基苄基尿嘧啶
• 英文名称: 5-benzyloxybenzyluracil
• 英文别名: 2,4(1H,3H)-Pyrimidinedione, 5-((3-(phenylmethoxy)phenyl)methyl)-；5-[(3-phenylmethoxyphenyl)methyl]-1H-pyrimidine-2,4-dione
• CAS: 28495-80-9
• 化学式: C₁₈H₁₆N₂O₃
• 分子量: 308.337
• InChiKey: ZJQDPXONNQFKKC-UHFFFAOYSA-N

物化性质

• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  5-苄氧基苄基尿嘧啶 在 氨 、 牛血清白蛋白 作用下， 以 甲醇 为溶剂， 反应 36.58h， 生成 5-(3-苄氧基苄基)-1-(2'-羟基乙氧基甲基)尿嘧啶
  参考文献：
  名称：

  Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.

  摘要：

  A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine-induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 mu M), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3-alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC(50)s of 0.047 and 0.027 mu M, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 mu M.

  DOI：

  10.1021/jm00019a015
• 作为产物：
  描述：

  3-邻羟基苯基丙酸乙酯 在 potassium carbonate 、 溶剂黄146 、 氯乙酸 、 lithium diisopropyl amide 作用下， 以 丙酮 为溶剂， 反应 18.0h， 生成 5-苄氧基苄基尿嘧啶
  参考文献：
  名称：

  Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.

  摘要：

  A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine-induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 mu M), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3-alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC(50)s of 0.047 and 0.027 mu M, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 mu M.

  DOI：

  10.1021/jm00019a015

文献信息

• Synthesis of variants of 5-benzylacyclouridine and 5-benzyloxybenzylacyclouridine
  作者：Shih-Hsi Chu、Zhi-Hao Chen、Zum-Yao Weng、Elizabeth C. Rowe、Edward Chu、Ming-Yu Wang Chu

  DOI：10.1002/jhet.5570230609

  日期：1986.11

  A number of variations and derivatives of BAU (5-benzylacyclouridine) and BBAU (5-benzyloxybenzylacy-clouridine), potent inhibitors of uridine phosphorylase were synthesized for evaluation as potential cancer chemotherapeutic agents. (“Acyclo” = 2′-hydroxymethoxymethyl-). These included a modification of the methylene group at N-1, esters of the terminal hydroxyl of the acyclo group, and extension

  合成了尿嘧啶磷酸化酶的有效抑制剂BAU（5-苄基环尿苷）和BBAU（5-苄氧基苄基-氯尿苷）的多种变体和衍生物，以评估其作为潜在的癌症化学治疗剂的能力。（“ Acyclo” ＝ 2'-羟基甲氧基甲基-）。这些包括在N-1处的亚甲基的修饰，无环基团的末端羟基的酯和在尿嘧啶碱基的5位的苄基链的延伸。BBBAU是细胞培养中非常好的FUdR增强剂。
• Synthesis of some halogenated and disubstituted amino benzylacyclouridine derivatives
  作者：Bai-Chuan Pan、Zhi-Hao Chen、Elizabeth C. Rowe、Shih-Hsi Chu

  DOI：10.1002/jhet.5570290402

  日期：1992.7

  1′-Halogenomethyl, 1′-azidomethyl and 1′-disubstituted aminomethyl derivatives of BAU (5-benzylacyclouridine) and BBAU (5-benzyloxybenzylacyclouridine) were synthesized in the course of our studies of benzylacyclouridines. Two new and more convenient preparations of the previously known aminomethyl-and hydroxymethyl-parent compounds of these two series, AM-BAU, AM-BBAU and HM-BBAU are also reported

  在研究苄基环尿苷的过程中，合成了BAU（5-苄基环尿苷）和BBAU（5-苄氧基苄基环尿苷）的1'-卤代甲基，1'-叠氮甲基和1'-二取代氨基甲基衍生物。还报道了这两个系列的先前已知的氨基甲基-和羟甲基-母体化合物的两种新的和更方便的制备，即AM-BAU，AM-BBAU和HM-BBAU。这些化合物是在寻找潜在的抗病毒药和嘧啶磷酸化酶抑制剂的过程中合成的。
• Synthesis of 5-benzyl and 5-benzyloxybenzyl-3′-azido-2′,3′-dideoxyuridine and their analogues as potential anti-AIDS agents
  作者：Bai-Chuan Pan、Zum-Yao Weng、Zhi-Hao Chen、Elizabeth C. Rowe、Shih-Hsi Chu

  DOI：10.1002/jhet.5570270609

  日期：1990.9

  5-Benzyl and 5-benzyloxybenzyl-substituted 3′-azido-2′,3′-dideoxyuridine, (8a and 8b), 3′-halogeno-2′,3′-dideoxyuridine, 9a, 9b, 10a, 10b, 11a and 11b, and 2′,3′-dideoxyuridine, 12a and 12b, of Scheme I were synthesized as potential anti AIDS agents. Synthesis of epimers of 8a and 8b, 5-benzyl- and 5-benzyloxybenzyl-1-(3′-azido-2′,3′-dideoxy-β-D-threo-pentafuranosyl)uracil, 15a and 15b, and 5-benzyl-

  5-苄基和5-苄氧基苄基取代的3'-叠氮基2'，3'-二脱氧尿苷，（8a和8b），3'-卤代2'，3'-二脱氧尿苷，9a，9b，10a，10b，11a合成了方案I的11b和11b以及2'，3'-二脱氧尿苷12a和12b作为潜在的抗AIDS剂。8a和8b，5-苄基和5-苄氧基苄基-1-（3'-叠氮基2'，3'-二脱氧-β-D-苏-五呋喃呋喃糖基）尿嘧啶，15a和15b和5-的差向异构体的合成还报道了方案II中所示的苄基-和5-苄氧基-5'-叠氮基-2'，5'-二脱氧尿苷16a和16b。
• Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine
  作者：Kazuo Hattori、Yasunori Kohchi、Nobuhiro Oikawa、Hitomi Suda、Masako Ura、Tohru Ishikawa、Masanori Miwa、Mika Endoh、Hiroyuki Eda、Hiromi Tanimura、Akira Kawashima、Ikuo Horii、Hideo Ishitsuka、Nobuo Shimma

  DOI：10.1016/s0960-894x(02)01082-x

  日期：2003.3

  A series of tumor-activated prodrugs of the inhibitors of dihydropyrimidine dehydrogenase (DPD), an enzyme catabolizing 5-fluorouracil (5-FU: 4g), has been designed and synthesized. RO0094889 (11c) is a prodrug of 5-vinyluracil (4c), a known DPD inhibitor, and was designed to generate 4c selectively in tumor tissues by sequential conversion of 11c by three enzymes: esterase, cytidine deaminase and thymidine phosphorylase, the latter two of which are known to be highly expressed in various tumor tissues. When capecitabine (1), a tumor-activated prodrug of 5-FU, was co-administered orally with 11c, 5-FU in tumor tissues was significantly increased with only a slight increase of 5-FU in plasma as compared with oral capecitabine alone. (C) 2003 Published by Elsevier Science Ltd.
• Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.
  作者：G. Faye Orr、David L. Musso、G. Evan Boswell、James L. Kelley、Suzanne S. Joyner、Stephen T. Davis、David P. Baccanari

  DOI：10.1021/jm00019a015

  日期：1995.9

  A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine-induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 mu M), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3-alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC(50)s of 0.047 and 0.027 mu M, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 mu M.